STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

UroGen Pharma (Nasdaq: URGN) will present at the Piper Sandler 37th Annual Healthcare Conference taking place December 2-4, 2025. The company is scheduled for a fireside chat on December 2, 2025 at 1:00 PM ET in New York, NY.

Investors can watch a live webcast and access a replay on UroGen’s Investor Relations website; the replay will be available for approximately 90 days.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Piper Sandler 37th Annual Healthcare Conference to take place on December 2-4, 2025.

Piper Sandler 37th Annual Healthcare Conference

Date / Time:December 2, 2025, at 1:00 PM ET
Format:Fireside Chat
Location:New York, NY
Webcast Link:here
  

Webcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for adult patients with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083


FAQ

When will UroGen (URGN) present at the Piper Sandler 2025 conference?

UroGen will present on December 2, 2025 during the Piper Sandler 37th Annual Healthcare Conference.

What time is the UroGen (URGN) presentation at the Piper Sandler conference?

The presentation is scheduled for 1:00 PM ET on December 2, 2025.

What is the format of UroGen’s (URGN) session at the Piper Sandler conference?

UroGen’s session will be a fireside chat in New York, NY.

Where can investors watch the UroGen (URGN) webcast for the Piper Sandler conference?

The live webcast and a replay will be available on UroGen’s Investor Relations website.

How long will the UroGen (URGN) conference replay be available after the event?

The replay will be available on the investor site for approximately 90 days.
Urogen Pharma

NASDAQ:URGN

URGN Rankings

URGN Latest News

URGN Latest SEC Filings

URGN Stock Data

1.21B
42.95M
6.87%
98.61%
15.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
RA'ANANA